Ads
related to: meningococcal meningitis immunization (menomune)- Meningitis B
Learn More About The Signs &
Symptoms Of Meningitis B.
- FAQs
Discover FAQs About Meningitis B &
Be Prepared With More Facts.
- Vaccine Locator Tool
Locate A Vaccine Provider Near You
With The Vaccine Locator Tool.
- What You Can Do
Find Out What You Can Do To Help
Protect Against Meningitis B.
- Meningitis B
Search results
Results From The WOW.Com Content Network
Meningococcal polysaccharide vaccine (MPSV-4), Menomune, has been available since the 1970s. It may be used if MCV-4 is not available, and is the only meningococcal vaccine licensed for people older than 55. Information about who should receive the meningococcal vaccine is available from the CDC. [24]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]
The first-of-its-kind shot addresses the five most common causes of meningococcal disease, Pfizer says. Vaccine aimed at preventing meningitis in kids approved by FDA. What happens next?
A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first ...
The Meningococcal Conjugate Vaccine (MCV4) is given between the ages of 11 and 12 years of age. As many as half the people who get meningococcal vaccines have mild side effect which include redness or pain at injection site; small percentage of people develop a fever; These symptoms usually only last 1 or 2 days [2]
Ad
related to: meningococcal meningitis immunization (menomune)